Back to News

Categories: News | Published On: December 14, 2023 | Written by Brandon Tilley |

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

Back to News
More News
  • Biolojic Design Appoints Neal Curran as Chief Business Officer
    Read More
  • Biolojic Design Joins Johnson & Johnson Innovation – JLABS
    Read More
BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com